April 3 next meeting of the Transparency Council.
AOTMiT: Transparency Council on lung cancer drugs and PNH, among others
Published March 28, 2023 08:11
The agenda includes:
Preparation of positions on drug evaluation:
Aspaveli (pegcetacoplan) under the drug program "Treatment of patients with nocturnal paroxysmal hemoglobinuria (PNH) (ICD-10 D59.5)."
Tecentriq (atezolizumab) under the drug program "Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)."
Preparation of an opinion on:
The rationale for amending the description of drug program B.122 "Preventive treatment of patients with recurrent attacks of severe hereditary angioedema (ICD-10: D 84.1)",
The possibility of using lanadelumab and a human C1-esterase inhibitor interchangeably under drug program B.122. "Preventive treatment of patients with recurrent attacks of severe hereditary angioedema (ICD-10: D 84.1)."
Preparation of an opinion on:
The legitimacy of moving medicinal products containing the active substance imatinib from the drug program B.3 "Treatment of Gastrointestinal Tumors of the Lining (GIST) (ICD-10 C 15, C 16, C 17, C 18, C 20, C 48)" to the catalog of reimbursable drugs in chemotherapy,
The legitimacy of including in the reimbursement catalog of reimbursable drugs in chemotherapy medicinal products containing the active substance imatinibum for off-label indications related to gastrointestinal lining tumor (GIST).
Preparation of an opinion on:
The appropriateness of moving medicinal products containing the active substance sorafenibum from the drug program B.3 "Treatment of gastrointestinal lining tumors (GIST) (ICD-10 C 15, C 16, C 17, C 18, C 20, C 48)" to the catalog of reimbursable drugs in chemotherapy,
The legitimacy of including in the reimbursement catalog of reimbursable drugs in chemotherapy medicinal products containing the active substance sorafenibum for off-label indications related to gastrointestinal lining tumor (GIST).
Preparation of an opinion on:
The appropriateness of transferring medicinal products containing the active substance sunitinbum from the drug program B.3 "Treatment of Gastrointestinal Tumors (GIST) (ICD-10 C 15, C 16, C 17, C 18, C 20, C 48)", B.10 "Treatment of patients with renal cell carcinoma (ICD-10: C64)" and B.53 "Treatment of highly differentiated neuroendocrine tumor of the pancreas (ICD-10 C25.4)" to the catalog of reimbursable drugs in chemotherapy.
The legitimacy of including in the reimbursement, in the catalog of reimbursable drugs in chemotherapy, medicinal products containing the active substance sunitinbum for off-label indications related to the treatment of the pediatric population under the drug program B.3 "Treatment of gastrointestinal lining tumors (GIST) (ICD-10 C 15, C 16, C 17, C 18, C 20, C 48)."
Preparation of a position paper on the appropriateness of issuing approvals for reimbursement of the drug Mytelase (ambenonii chloridum) for the indication: myasthenia gravis pseudomotility.
Preparation of opinions on draft health policy programs of local government units:
"Program of infertility treatment by in vitro fertilization for residents of the city of Olesnica in 2023-2024". ,
"Treatment of infertility by in vitro fertilization for residents of the Municipality of Starogard Gdański in 2023-2026".
Source: AOTMiT
